Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
CC transcript
Director departure
Quarterly results
IMMUNE PHARMACEUTICALS INC (IMNPQ) Create: Alert

All | News | Filings
Date FiledTypeDescription
04/13/2021 8-K Quarterly results
04/12/2021 8-K Quarterly results
03/08/2019 8-K Bankruptcy or Receivership, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officer...
Docs: "EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT is entered into as of March 7, 2019, by and between Gary H. Rabin , and Immune Pharmaceuticals Inc . Company desires to engage Rabin as President and Interim Chief Executive Officerto provide certain services to Company as more particularly set forth in Exhibit A attached hereto and made a part hereof . The parties desire to set forth, in writing, the terms and conditions concerning the engagement. Accordingly, in consideration of the mutual covenants in this Agreement, and for other good and valuable consideration, it is agreed as follows: 1. Engagement and Commencement Date. Commencing on March 7, 2019 , Company hereby engages Rabin as President and Interim Chief Executive Officer, on the terms and conditions set forth in this Agreement. By ...",
"Investor Contact"
02/14/2019 8-K Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arran...
Docs: "Notice of Default and Notice of Sale of Collateral"
12/19/2018 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders...
Docs: "Certificate of Amendment of Third Amended and Restated Certificate of Incorporation of Immune Pharmaceuticals Inc"
12/06/2018 8-K Other Events, Financial Statements and Exhibits
Docs: "Immune Pharmaceuticals Announces Adjournment of Special Meeting of Stockholders"
11/28/2018 8-K Other Events, Financial Statements and Exhibits
Docs: "Immune Pharmaceuticals and Vector Therapeutics Sign Option Agreement for Worldwide Ceplene® Rights"
11/26/2018 8-K Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arran...
10/22/2018 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
10/10/2018 8-K Quarterly results
09/18/2018 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
Docs: "Securities Purchase Agreement, by and between Immune Pharmaceuticals, Inc. and Power Up Lending Group Ltd",
"Convertible Promissory Note, by and between Immune Pharmaceuticals, Inc. and Power Up Lending Group Ltd"
09/10/2018 8-K Resignation/termination of a director
07/26/2018 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure...
Docs: "Immune Pharmaceuticals Receives Nasdaq Delisting Determination; Eligible to trade Over-the-Counter July 26, 2018"
06/08/2018 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure...
Docs: "Investor Contact:"
05/14/2018 8-K Quarterly results
05/07/2018 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Immune Pharmaceuticals Provides Update on Plans for Oncology Subsidiary, Cytovia, Inc.,"
02/28/2018 8-K Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Immune Pharmaceuticals Announces Outcome of Annual Meeting of Stockholders"
02/12/2018 8-K Investor presentation
Docs: "Company slide presentation"
02/08/2018 8-K Other Events, Financial Statements and Exhibits
Docs: "Press Release"
01/26/2018 8-K Other Events, Financial Statements and Exhibits
Docs: "Immune Pharmaceuticals Announces Adjournment of Annual Meeting"
01/09/2018 8-K Investor presentation
Docs: "Company slide presentation"
12/06/2017 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
12/04/2017 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Employment Agreement, by and between Immune Pharmaceuticals, Inc. and Elliot Maza"
11/27/2017 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Departure of Directors o...
11/17/2017 8-K Other Events, Financial Statements and Exhibits
Docs: "Unaudited pro forma condensed consolidated balance sheet"
10/25/2017 8-K Quarterly results
10/23/2017 8-K Other Events, Financial Statements and Exhibits
Docs: "IMMUNE PHARMACEUTICALS INC. ANNOUNCES CLOSING OF $18,000,000 PUBLIC OFFERING OF CONVERTIBLE PREFERRED STOCK AND WARRANTS ENGLEWOOD CLIFFS, N.J., – Immune Pharmaceuticals Inc. a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, today announced the closing of its previously announced public offering of units for gross proceeds of $18,000,000, which excludes underwriting discounts and commissions and offering expenses payable by Immune. The offering was comprised of units, priced at a public offering price of $1,000 per unit. Each unit consists of one share of Series E Convertible Preferred Stock and 982 warrants , each of which entitles the holder to purchase one share of Immune’ s common stock. The Warrants are initial...",
"About Immune Pharmaceuticals Inc."
10/03/2017 8-K Investor presentation
Docs: "Immune Pharmaceuticals, Inc. Corporate Presentation, dated October, 2017"
09/08/2017 8-K Quarterly results
08/29/2017 8-K Quarterly results
08/24/2017 8-K Quarterly results
08/18/2017 8-K Quarterly results
07/18/2017 8-K Form 8-K - Current report:
07/12/2017 8-K Form 8-K - Current report:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy